The Rise Of Virulence And Antibiotic Resistance In Staphylococcus Aureus

Staphylococcus aureus S. aureus is a growing issue both within hospitals and community because of its virulence determinants and the continuing emergence of new strains resistant to antimicrobiotics. In this book, we present the state of the art of S. aureus virulence mechanisms and antibiotic-resistance profiles, providing an unprecedented and comprehensive collection of up-to-date research about the evolution, dissemination, and mechanisms of different staphylococcal antimicrobial resistance patterns alongside bacterial virulence determinants and their impact in the medical field. We include several review chapters to allow readers to better understand the mechanisms of methicillin resistance, glycopeptide resistance, and horizontal gene transfer and the effects of alterations in S. aureus membranes and cell walls on drug resistance. In addition, we include chapters dedicated to unveiling S. aureus pathogenicity with the most current research available on S. aureus exfoliative toxins, enterotoxins, surface proteins, biofilm, and defensive responses of S. aureus to antibiotic treatment.

Staphylococcus was first recognized as a human pathogen in 1880 and was named for its grape cluster-like appearance. In 1884, Staphylococcus aureus was identified and named for its vibrant golden color, which was later found to be the result of golden toxin production. Here, experts examine in-depth patterns of S. aureus colonization and exposures in humans, mammals, and birds that have led to the development of various clinical diseases. The mode of transmission of S. aureus and different methods for its detection in different samples are defined. Conventional antibiotic options to treat this aggressive, multifaceted, and readily adaptable pathogen are becoming limited. Alternative, novel chemotherapeutics to target S. aureus are discussed in the pages within, including herbal medicines, bee products, and modes of delivery.

Staphylococcus aureus is a coccus, gram-positive, non-spore forming, and non-motile bacterium. Its commensal and opportunistic capabilities make it able to colonize different sites of animals and humans. Resistance to antibiotics has resulted in development of new strains and new types within strains. Types of methicillin-resistant S. aureus (MRSA) include hospital-acquired MRSA (HA-MRSA), community-acquired MRSA (CA-MRSA), and livestock-acquired MRSA (LA-MRSA). There are also new strains like vancomycin-resistant S. aureus (VRSA) and vancomycin-intermediate S. aureus (VISA). Expansion in resistance is expected to give rise to newer strains resistant to antibiotics such as macrolide (erm gene), tetracycline (tet genes), mupirocin (mupR), and fusidic acid (fusD). Alternative approaches like nanoparticles, bacteriophages, phytochemicals, and more are required to tackle this pathogen. This book contains information on epidemiology, resistance mechanisms, and alternative ways to curtail S. aureus infection, as well as future research opportunities.

Multiple relationships exist between antimicrobial resistance and bacterial virulence, and the spread of clones combining multiple antibiotic resistance and a high virulence level is an increasing problem. It was previously described how mutation-driven or horizontally acquired resistance mechanisms can also have effects on virulence. It was also reported that mobile genetic elements often carry both resistance determinants and virulence-modulating genes, which favors the co-selection of both traits. In the present volume, we present a collection of articles which document additional aspects of the interactions between antimicrobial resistance and virulence in bacteria, and describe their potential therapeutic consequences.

AN AUTHORITATIVE SURVEY OF CURRENT RESEARCH INTO CLINICALLY USEFUL CONVENTIONAL AND NONCONVENTIONAL ANTIBIOTIC THERAPEUTICS Pharmaceutically-active antibiotics revolutionized the treatment of infectious diseases, leading to decreased mortality and increased life expectancy. However, recent years have seen an alarming rise in the number and frequency of antibiotic-resistant "Superbugs." The Centers for Disease Control and Prevention (CDC) estimates that over two million antibiotic-resistant infections occur in the United States annually, resulting in approximately 23,000 deaths. Despite the danger to public health, a minimal number of new antibiotic drugs are currently in development or in clinical trials by major pharmaceutical companies. To prevent reverting back to the pre-antibiotic era—when diseases caused by parasites or infections were virtually untreatable and frequently resulted in death—new and innovative approaches are needed to combat the increasing resistance of pathogenic bacteria to antibiotics. Bacterial Resistance to Antibiotics – From Molecules to Man examines the current state and future direction of research into developing clinically-useful next-generation novel antibiotics. An internationally-recognized team of experts cover topics including glycopeptide antibiotic resistance, anti-tuberculosis agents, anti-virulence therapies, tetracyclines, the molecular and structural determinants of resistance, and more. Presents a multidisciplinary approach for the optimization of novel antibiotics for maximum potency, minimal toxicity, and appropriated degradability Highlights critical aspects that may relieve the problematic medical situation of antibiotic resistance Includes an overview of the genetic and molecular mechanisms of antibiotic resistance Addresses contemporary issues of global public health and longevity Includes full references, author remarks, and color illustrations, graphs, and charts Bacterial Resistance to Antibiotics – From Molecules to Man is a valuable source of up-to-date information for medical practitioners, researchers, academics, and professionals in public health, pharmaceuticals, microbiology, and related fields.

This volume covers all aspects of the antibiotic discovery and development process through Phase II/III. The contributors, a group of highly experienced individuals in both academics and industry, include chapters on the need for new antibiotic compounds, strategies for screening for new antibiotics, sources of novel synthetic and natural antibiotics, discovery phases of lead development and optimization, and candidate compound nominations into development. Beyond discovery , the handbook will cover all of the studies to prepare for IND submission: Phase I (safety and dose ranging), progression to Phase II (efficacy), and Phase III (capturing desired initial indications). This book walks the reader through all aspects of the process, which has never been done before in a single reference. With the rise of antibiotic resistance and the increasing view that a crisis may be looming in infectious diseases, there are strong signs of renewed emphasis in antibiotic research. The purpose of the handbook is to offer a detailed overview of all aspects of the problem posed by antibiotic discovery and development.

Topic Editors Dr. Bagnoli and Dr. Phogat are employed by GlaxoSmithKline plc. The other Topic Editors Declare no conflict of interest in relation to the Research Topic theme